Novartis' Pluvicto Expected to Dominate Prostate Cancer Radiopharmaceutical Market
Is Johnson & Johnson (JNJ) the Best Future Stock For The Long-Term?
Express News | Johnson & Johnson subsidiary applies for bankruptcy protection due to talcum powder-caused cancer issues.
Sanofi Sarclisa Combo Gains Approval as First-line Multiple Myeloma Treatment
Johnson & Johnson Boosts Talc Settlement Payment to $8 Billion in Unit's Bankruptcy Case
Johnson & Johnson Files Third Bankruptcy Case Seeking to End Talc Lawsuits -- WSJ
Express News | Johnson & Johnson Shares Lose Ground Very Slightly, Last Down 0.6%
Express News | johnson & johnson (JNJ): In the baby powder cancer case, 83% of the plaintiffs support the company's proposed bankruptcy reorganization plan. The settlement costs have been further increased to over 8 billion US dollars.
Express News | J&J: Contemplated Settlement Represents Present Value of About $8 Bln to Be Paid Over 25 Years, Totaling About $10 Billion Nominal
Express News | J&J: Company Reiterates That None of Talc-Related Claims Against It Have Merit
Express News | J&J: Plan Would Resolve 99.75% of All Pending Talc Lawsuits Against Johnson & Johnson and Its Affiliates in the United States
Express News | J&J -Approximately 83% of Current Claimants and the Future Claims Representative Support the Proposed Bankruptcy Plan
Express News | J&J - Red River Increased Its Settlement Commitment by $1.75 Billion to Approximately $8 Billion
Express News | Johnson & Johnson Announces That Its Subsidiary, Red River Talc LLC, Has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
Johnson & Johnson Myeloma Treatment Gets Approval Recommendation in Europe
Express News | Darzalex® (Daratumumab)-Based Quadruplet Regimen Receives Positive Chmp Opinion for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $175 Price Target
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $175
RBC Capital analyst Shagun Singh Chadha maintains $Johnson & Johnson(JNJ.US)$ with a buy rating, and maintains the target price at $175.According to TipRanks data, the analyst has a success rate of 49
Johnson & Johnson (JNJ.US) has increased the settlement amount for baby powder cancer lawsuits to over $8.2 billion.
According to sources, Johnson & Johnson (JNJ.US) has increased the settlement amount for thousands of lawsuits accusing its baby powder of causing cancer to over $8.2 billion, up from the previous proposed settlement amount of $6.5 billion.
Johnson & Johnson (JNJ) Gets a Buy From RBC Capital